Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 7;12(12):2052.
doi: 10.3390/life12122052.

The Role of Non-Alcoholic Fatty Liver Disease in Infections

Affiliations
Review

The Role of Non-Alcoholic Fatty Liver Disease in Infections

Juraj Krznarić et al. Life (Basel). .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, affecting one third of the Western population. The hallmark of the disease is excessive storage of fat in the liver. Most commonly, it is caused by metabolic syndrome (or one of its components). Even though the development of NAFLD has multiple effects on the human organism resulting in systemic chronic low-grade inflammation, this review is focused on NAFLD as a risk factor for the onset, progression, and outcomes of infectious diseases. The correlation between NAFLD and infections is still unclear. Multiple factors (obesity, chronic inflammation, altered immune system function, insulin resistance, altered intestinal microbiota, etc.) have been proposed to play a role in the development and progression of infections in people with NAFLD, although the exact mechanism and the interplay of mentioned factors is still mostly hypothesized. In this article we review only the selection of well-researched topics on NAFLD and infectious diseases (bacterial pneumonia, COVID, H. pylori, urinary tract infections, C. difficile, bacteremia, hepatitis B, hepatitis C, HIV, and periodontitis).

Keywords: C. difficile; COVID-19; H. pylori; HIV; NAFLD; bacteremia; community acquired pneumonia; hepatitis B; hepatitis C; infectious disease; periodontitis; urinary tract infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Immunological pathways that associate NAFLD and infections.

References

    1. Puri P., Sanyal A.J. Nonalcoholic fatty liver disease: Definitions, risk factors, and workup. Clin. Liver Dis. 2012;1:99–103. doi: 10.1002/cld.81. - DOI - PMC - PubMed
    1. Barbosa J.V., Lai M. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. Hepatol. Commun. 2020;5:158–167. doi: 10.1002/hep4.1618. - DOI - PMC - PubMed
    1. Abd El-Kader S.M., El-Den Ashmawy E.M.S. Non-alcoholic fatty liver disease: The diagnosis and management. World J. Hepatol. 2015;7:846–858. doi: 10.4254/wjh.v7.i6.846. - DOI - PMC - PubMed
    1. Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2017;15:11–20. doi: 10.1038/nrgastro.2017.109. - DOI - PubMed
    1. DiStefano J.K. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology. 2020;161:bqaa134. doi: 10.1210/endocr/bqaa134. - DOI - PMC - PubMed

LinkOut - more resources